Acinetobacter baumannii Clinical Isolates Resist Complement-Mediated Lysis by Inhibiting the Complement Cascade and

Michal Magda1, Wendy Boschloo1, Serena Bettoni1

  • 1Department of Translational Medicine, Lund University, Malmö, Sweden.

PubMed
Abstract

Insights

Acinetobacter baumannii strains with specific capsule types evade the human complement system, leading to increased serum resistance and virulence. Understanding this relationship is key to combating these dangerous infections.

Area of Science:

  • Immunology
  • Microbiology
  • Genetics

Background:

  • Acinetobacter baumannii is a dangerous opportunistic pathogen.
  • The human complement system, including the membrane attack complex (MAC), defends against bacterial infections.
  • A. baumannii employs evasion strategies against complement-mediated lysis.

Purpose of the Study:

  • To investigate the mechanisms by which A. baumannii evades complement.
  • To determine the role of capsule type in complement resistance and virulence.

Main Methods:

  • Flow cytometry and Western blotting for complement deposition.
  • ELISA for soluble MAC formation.
  • SYTOX Green Assay for serum resistance.
  • Galleria mellonella infection model.
  • Whole genome sequencing.

Main Results:

  • 11 of 16 clinical isolates showed MAC deposition; 5 did not.
  • MAC-negative isolates exhibited increased serum resistance and virulence.
  • MAC-negative isolates inhibited alternative pathway activation.
  • Genome sequencing revealed more virulence genes in MAC-negative strains.
  • Distinct capsule types were associated with MAC deposition or inhibition (e.g., KL171 vs. KL230).

Conclusions:

  • Capsule type is linked to complement resistance in A. baumannii.
  • A. baumannii capsule type influences virulence and evasion of innate immunity.
  • Findings highlight the interplay between bacterial genetics, immune evasion, and pathogenesis.